Deutsche Bank AG Has $3.93 Million Stake in Glaukos Corporation $GKOS

Key Points

• Deutsche Bank AG reduced its position in Glaukos Corporation by 8.9% in Q1, owning 39,936 shares valued at approximately $3.93 million.
• Several hedge funds notably increased their holdings in Glaukos, with Whipplewood Advisors LLC raising its position by 3,957.1%.
• Analysts have a consensus price target of $127.42 for Glaukos, with ratings ranging from "sell" to "strong-buy" among different financial institutions.

Deutsche Bank AG reduced its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 8.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,936 shares of the medical instruments supplier's stock after selling 3,923 shares during the period. Deutsche Bank AG owned approximately 0.07% of Glaukos worth $3,931,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Bessemer Group Inc. grew its holdings in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares during the period. Whipplewood Advisors LLC grew its holdings in Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. grew its holdings in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc grew its holdings in Glaukos by 583.9% during the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 327 shares during the period. Finally, CoreCap Advisors LLC grew its holdings in Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after acquiring an additional 200 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Wells Fargo & Company lifted their price target on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Morgan Stanley dropped their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. UBS Group lifted their price target on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. William Blair raised Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Needham & Company LLC dropped their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Stock Up 4.9%

NYSE:GKOS traded up $4.4170 on Friday, hitting $94.2070. 688,079 shares of the company's stock traded hands, compared to its average volume of 1,214,021. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The firm has a 50-day moving average price of $96.26 and a 200-day moving average price of $101.08. The company has a market cap of $5.40 billion, a PE ratio of -57.10 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. During the same quarter in the previous year, the business posted ($0.52) EPS. The business's revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.